The controllable assembly of metal-organic frameworks (MOFs) nanomaterials is an effective means to enhance their application capabilities. In this paper, a novel method is reported to control MOFs assembly by using a DNA framework material, a tetrahedral DNA nanostructure (TDN) labeled with phosphate groups at the vertex. In particular, various well-defined superstructures can be tailored by regulating the number of phosphate groups that coordinate with catalytic Zr-MOFs to create polymeric MOFs superstructures (Poly(MOFs)), exhibiting excellent catalytic activities and molecular recognition ability as well as greatly amplified signal readout. Furthermore, based on the DNA framework-controlled Poly(MOFs), a colorimetric biosensor with excellent analytical performance is fabricated for improving the diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. It is demonstrated that the quantification of HER2 protein can be achieved at molecular level with the limit of detection (LOD) of 12 pg L^-1 and cellular level with the LOD of 10 cells. More importantly, the detection of HER2 in the serum of breast cancer patients have been achieved, thus HER2-positive and triple-negative breast cancer patients can be well distinguished. Considering the substitutability of the target, this study shows great potential in biomedical research as well as clinical applications.

金属有机骨架（MOF）纳米材料的可控组装是增强其应用能力的有效手段。在本文中，报道了一种通过使用DNA框架材料来控制 MOF 组装的新方法，这种材料是一种在顶点用磷酸基团标记的四面体 DNA 纳米结构 (TDN) 。特别是，可以通过调节与催化Zr-MOFs配合的磷酸基团的数量来定制各种明确的超结构，以创建聚合MOFs超结构（Poly（MOFs）），表现出优异的催化活性和分子识别能力，并大大放大信号读出。此外，基于DNA框架控制的Poly(MOFs)，制备了具有优异分析性能的比色生物传感器，用于改善人表皮生长因子受体2(HER2)阳性乳腺癌的诊断。结果表明，HER2蛋白的定量可以在分子水平上实现，检测限(LOD)为12 pg L ^-1，在细胞水平上定量，LOD为10个细胞。更重要的是，实现了乳腺癌患者血清中HER2的检测考虑到靶点的可替代性，本研究在生物医学研究和临床应用方面显示出巨大的潜力。